Abbott, Other Stent Makers Seek Toss Of Off-Label FCA Suit

Law360, New York (October 23, 2012, 12:53 PM EDT) -- Boston Scientific Corp., Abbott Laboratories and a Johnson & Johnson unit on Monday urged a Texas federal judge to end a former Guidant Corp. employee's long-running whistleblower litigation over off-label marketing of digestive tract stents, arguing he still hasn't sufficiently alleged False Claims Act violations.

Plaintiff Kevin Colquitt filed his fourth amended complaint against the companies Sept. 14 after his previous complaints had been dismissed. However, Boston Scientific, Abbott and J&J's Cordis Corp. argued in separate briefs that Colquitt had failed to provide any information supporting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.